RecruitingNCT01281735
International Chronic Myeloid Leukemia Pediatric Study
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Poitiers University Hospital
- Principal Investigator
- Frederic MILLOT, MDPoitiers University Hospital
- Enrollment
- 750 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2028
Study locations (20)
- Women's and children's Hospital, North Adelaide, South Australia, Australia
- St. Anna Children's Cancer Research Institute and St. Anna Children's Hospital, Vienna, Austria
- Belarussian Reseach Center for Pediatric Oncology and hematology (BRCPOH), Minsk, Belarus
- University Hospital of Ghent, Ghent, Belgium
- Instituto de Oncologia Pediatrica, São Paulo, Brazil
- Hospital Roberto Del Rio, Santiago, Chile
- Prince of Wales Hospital, Hong Kong, China
- Children's Hospital Zagreb, Zagreb, Croatia
- Charles University Motol, Prague, Czechia
- Rigshospitalet, Copenhagen, Denmark
- Clinical Investigation Center CIC 1402, Poitiers, France
- University Hospital Dresden, Dresden, Germany
- Agia Sophia Children's Hospital, Athens, Greece
- Keio University School of Medicine, Tokyo, Japan
- Saint George Hospital University Medical Centre, Beirut, Lebanon
- +5 more locations on ClinicalTrials.gov
Collaborators
CIC Inserm 1402 · University of Milano Bicocca · University Medical Center Groningen · University of Liege · Imperial College London · University Hospital Dresden · International BFM Study Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01281735 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics